Release Date: October 31, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you discuss the trajectory of the CIDP launch and any variables affecting it? A: Karen Massey, Chief Operating Officer, explained that the CIDP launch has been relatively linear without a bolus of patient starts. The dynamics are as expected, with payer policies taking two quarters to establish. About 54% of commercial lives are covered, and the prescriber base is expanding. Metrics relevant to the launch's progress will continue to be provided, but not specific revenue or patient guidance.
Q: How long does it take for a CIDP patient to receive treatment from the time the prescription is written? A: Karen Massey noted that the time from prescription to treatment is in line with expectations and similar to MG. The process is smoother when payer policies are in place, and the team is working efficiently to support patients through this process.
Q: What percentage of CIDP patients are switching from IVIg, and what about those who aren't? A: Tim Van Hauwermeiren, CEO, stated that about 85% of CIDP patients are switching from IVIg, which aligns with expectations. The remaining 15% are primarily coming from steroids or other immunosuppressants.
Q: Can you provide more details on the payer formulary coverage for CIDP? A: Karen Massey explained that payer policies generally require some prior IVIg or subcutaneous IG use, but not specific documentation of response rates. The policies are favorable, allowing for documentation of prior use at any time in the patient's history.
Q: How do you view the opportunity for ARGX-121 in IgA nephropathy compared to competitors? A: Tim Van Hauwermeiren expressed excitement about ARGX-121, highlighting its selectivity and precision in eliminating pathogenic antibodies. He believes it holds promise for superior clinical efficacy compared to current data from competitors.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.